XML 126 R110.htm IDEA: XBRL DOCUMENT v3.25.0.1
BUSINESS COMBINATIONS AND ASSET ACQUISITIONS - Narrative (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 12, 2023
Aug. 02, 2022
May 02, 2022
May 31, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Aug. 23, 2023
Dec. 31, 2021
Acquisition                  
Contingent consideration, liability         $ 282,212,000 $ 288,657,000 $ 306,927,000   $ 359,021,000
Stock issued during period, value, acquisitions           1,675,000 14,792,000    
Consideration transferred, net of cash acquired         0 52,413,000 $ 14,686,000    
Noncash or part noncash divestiture, amount of consideration received, fair value   $ 6.70              
Finite-lived Intangible assets, net         589,693,000 640,396,000      
Period of lab testing services   24 months              
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]             Other operating income (loss)    
Acquired Finite-Lived Intangible Assets [Line Items]                  
Contract with Customer, Receivable, after Allowance for Credit Loss         56,600,000 31,600,000      
Contract with Customer, Asset, after Allowance for Credit Loss         25,900,000 41,700,000      
Disposal Group, Disposed of by Sale, Not Discontinued Operations | Oncotype DX Genomic Prostate Score Test                  
Acquisition                  
Total consideration   $ 29,631,000              
Noncash or part noncash divestiture, amount of consideration received, shares   691,171              
Disposal group, contingent consideration arrangements, range of outcomes, value, high   $ 70,000,000           $ 82,500,000  
Finite-lived Intangible assets, net   $ 42,900,000              
Disposal group, not discontinued operation, gain (loss) on disposal             $ 13,200,000    
Disposal Group, Contingent Consideration Arrangements, Gain (Loss)         9,200,000 73,300,000      
Acquired Finite-Lived Intangible Assets [Line Items]                  
Disposal Group, Contingent Consideration Arrangements, Gain (Loss)         9,200,000 73,300,000      
Customer relationships                  
Acquisition                  
Finite-lived Intangible assets, net         $ 2,667,000 $ 3,111,000      
Acquired Finite-Lived Intangible Assets [Line Items]                  
Finite-Lived Intangible Asset, Useful Life         6 years 7 years      
Trade name                  
Acquisition                  
Finite-lived Intangible assets, net         $ 68,847,000 $ 76,097,000      
Acquired Finite-Lived Intangible Assets [Line Items]                  
Finite-Lived Intangible Asset, Useful Life         10 years 9 months 18 days 11 years 7 months 6 days      
OmicEra                  
Acquisition                  
Business Combination, Consideration Transferred     $ 19,408,000            
Equity issued to acquire business (in shares)       265,186          
Shares issued, price per share (in usd per share)     $ 55.78            
Contingent payment obligations     $ 6,000,000            
Contingent consideration, liability     4,600,000            
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable     $ 14,792,000            
OmicEra Diagnostics Acquisition                  
Acquisition                  
Equity issued to acquire business (in shares)       265,186          
Resolution Bioscience                  
Acquisition                  
Business Combination, Consideration Transferred $ 54,202,000                
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles 26,000,000                
Payments to Acquire Businesses, Gross 52,527,000                
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable $ 1,675,000                
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method 4.6 million                
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory $ 2,900,000                
Acquired Finite-Lived Intangible Assets [Line Items]                  
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method 4.6 million                
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Compensatory $ 2,900,000                
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable Fair Value Method 4.6 million